MIRA vs REGN · $41.1M cap vs P/E 14, rev $4.29B
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is a drug manufacturers - general company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
MIRA does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MIRA currently screens at market cap $41.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MIRA and REGN stock pages for the full models.
Not investment advice.